Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of "Hold" From Analysts
Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Recommendation of "Hold" From Analysts
Hims & Hers Health, Inc. (NYSE:HIMS – Get Rating) has been given an average rating of "Hold" by the eight analysts that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $7.38.
据MarketBeat报道,Hims&Hers Health,Inc.(纽约证券交易所代码:HIMS-GET Rating)目前追踪该公司的八位分析师给出的平均评级为“持有”。一名分析师对该股给予了卖出建议,两名分析师给出了持有建议,两名分析师对该公司提出了买入建议。在过去一年发布该股报告的券商中,1年目标价的平均水平为7.38美元。
A number of research analysts have recently issued reports on the stock. SVB Leerink boosted their price target on shares of Hims & Hers Health from $4.00 to $5.00 and gave the stock an "underperform" rating in a research report on Tuesday, August 9th. Credit Suisse Group boosted their price target on shares of Hims & Hers Health from $7.00 to $8.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 10th. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Hims & Hers Health from $7.00 to $8.00 in a research report on Wednesday, August 10th. Guggenheim lifted their price objective on shares of Hims & Hers Health to $12.00 in a research note on Monday, August 15th. Finally, Truist Financial began coverage on shares of Hims & Hers Health in a research note on Wednesday, September 7th. They issued a "hold" rating and a $7.00 price objective for the company.
一些研究分析师最近发布了关于该股的报告。SVB Leerink在8月9日周二的一份研究报告中将Hims&Hers Health的目标价从4.00美元上调至5.00美元,并将该股的评级定为“表现不佳”。瑞士信贷集团将Hims&Hers Health的股票目标价从7.00美元上调至8.00美元,并在8月10日(星期三)的一份研究报告中给予该股“跑赢大盘”的评级。德意志银行Aktiengesellschaft在8月10日星期三的一份研究报告中将Hims&Hers Health的股票目标价从7.00美元上调至8.00美元。古根海姆在8月15日星期一的一份研究报告中将Hims&Hers Health的股票目标价上调至12.00美元。最后,Truist Financial在9月7日星期三的一份研究报告中开始报道Hims&Hers Health的股票。他们对该公司的评级为“持有”,目标价为7美元。
Insiders Place Their Bets
内部人士下注
In related news, insider Irene Becklund sold 11,002 shares of the business's stock in a transaction dated Friday, September 9th. The shares were sold at an average price of $6.64, for a total value of $73,053.28. Following the transaction, the insider now directly owns 2,715 shares of the company's stock, valued at approximately $18,027.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Lynne Chou O'keefe sold 10,046 shares of the business's stock in a transaction dated Tuesday, September 20th. The shares were sold at an average price of $5.68, for a total value of $57,061.28. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Irene Becklund sold 11,002 shares of the business's stock in a transaction dated Friday, September 9th. The stock was sold at an average price of $6.64, for a total transaction of $73,053.28. Following the completion of the transaction, the insider now directly owns 2,715 shares in the company, valued at $18,027.60. The disclosure for this sale can be found here. Insiders have sold 51,047 shares of company stock valued at $287,364 in the last three months. 35.22% of the stock is currently owned by insiders.
在相关新闻中,内部人士艾琳·贝克伦德在一笔日期为9月9日星期五的交易中出售了11,002股该公司股票。这些股票的平均价格为6.64美元,总价值为73,053.28美元。交易完成后,这位内部人士现在直接持有该公司2,715股股票,价值约18,027.60美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过这个环节。在相关新闻中,董事在日期为9月20日(星期二)的交易中出售了10,046股该公司股票。这些股票的平均价格为5.68美元,总价值为57,061.28美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过美国证券交易委员会网站。此外,内部人士艾琳·贝克伦德在一笔日期为9月9日星期五的交易中出售了11,002股该公司股票。该股以6.64美元的平均价格出售,总成交金额为73,053.28美元。交易完成后,这位内部人士现在直接拥有该公司2,715股,价值18,027.60美元。关于这次销售的披露可以找到这里。在过去的三个月里,内部人士已经出售了51,047股公司股票,价值287,364美元。35.22%的股份目前由内部人士持有。
Institutional Inflows and Outflows
机构资金流入和流出
Hims & Hers Health Price Performance
HIS和HIS的健康价格表现
Hims & Hers Health stock opened at $5.38 on Wednesday. The business has a 50 day moving average of $6.20 and a 200-day moving average of $5.12. Hims & Hers Health has a 1 year low of $2.72 and a 1 year high of $9.19. The company has a market capitalization of $1.10 billion, a P/E ratio of -13.12 and a beta of 0.46.
周三,His&Hers Health的股票开盘报5.38美元。该业务的50日移动均线切入位在6.20美元,200日移动均线切入位在5.12美元。Hims&Hers Health的一年低点为2.72美元,一年高位为9.19美元。该公司市值为11.亿美元,市盈率为-13.12,贝塔系数为0.46。
Hims & Hers Health (NYSE:HIMS – Get Rating) last posted its earnings results on Monday, August 8th. The company reported ($0.10) EPS for the quarter, hitting the consensus estimate of ($0.10). Hims & Hers Health had a negative net margin of 22.22% and a negative return on equity of 23.24%. The business had revenue of $113.60 million for the quarter, compared to the consensus estimate of $103.89 million. During the same period last year, the company earned ($0.08) EPS. The firm's revenue was up 89.0% compared to the same quarter last year. Equities analysts anticipate that Hims & Hers Health will post -0.36 EPS for the current year.
Hims&Hers Health(纽约证券交易所代码:HIMS-GET Rating)最近一次公布财报是在8月8日星期一。该公司公布本季度每股收益(0.10美元),超过了普遍预期的(0.10美元)。Hims&Hers Health的净利润率为负22.22%,股本回报率为负23.24%。该业务本季度的收入为1.136亿美元,而普遍预期为1.0389亿美元。去年同期,该公司每股收益为0.08美元。与去年同期相比,该公司的收入增长了89.0%。股票分析师预计,Hims&Hers Health本年度每股收益将为0.36欧元。
About Hims & Hers Health
关于希姆斯和她的健康
(Get Rating)
(获取评级)
Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care.
Hims&Hers Health,Inc.运营着一个多专业远程医疗平台,将消费者与有执照的医疗保健专业人员联系起来。该公司提供一系列健康和健康产品和服务,可在其网站和移动应用程序上直接由客户购买。它还提供定期的处方药和医疗保健提供者的持续护理;以及非处方药和设备产品、化妆品和补充剂产品,主要侧重于健康、性健康和健康、皮肤护理和头发护理。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Hims & Hers Health (HIMS)
- Defensive Stocks For A Volatile Market
- Will UPS Be Next to Deliver a Warning?
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
- 免费获取StockNews.com关于他和她的健康的研究报告(HIMS)
- 防御性股票应对动荡的市场
- UPS会成为下一个发出警告的公司吗?
- SunPower准备推动三位数的收益增长
- 这是Gap Stock黎明前最黑暗的一次吗?
- 与捷普公司一起打造更好的技术产品组合。
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
接受《健康日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Hims&Hers Health和相关公司的最新新闻和分析师评级的每日简要摘要。